In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

Indian equities fell on August 12, with the Nifty 50 down 0.40% and the S&P BSE Sensex down 0.46%. Investors were cautious ahead of US inflation data, which could influence the Federal Reserve's ...

One of the most significant biomedical achievements of the 21st century, mRNA vaccines have reshaped the world’s ability to ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for ...

The FDA has agreed to fast-track its review of gepotidacin, an oral antibiotic already approved for urinary tract infections, ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...